Tony Coles, Cerevel CEO

Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

Neu­ro­science biotech Cerev­el Ther­a­peu­tics said da­ta read­outs for sev­er­al clin­i­cal tri­als will come lat­er than orig­i­nal­ly ex­pect­ed, and al­so dis­closed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA